UNSPSC 51384102: Metbufen

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H16O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8AE88M5N5V, chemically known as propionic acid, 3-(4-biphenylylcarbonyl)-2-methyl- but generally known as metbufen, which bears US NIH Compound Identifier 68823. European Medicines Agency schedules Metbufen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08821MIG.

UNSPSC 51384102 Metbufen is a Commodity code that does not align with the recent state and local procurement activity tagged under it. The source contains three recent opportunities — a Seminole County, Florida IFB for naloxone and drug deactivation systems (posted June 30, 2026), a Texas HHS RFI for direct-to-manufacturer prescription programs (posted April 3, 2026), and a Minnesota MMCAP RFP for generic multi-source pharmaceuticals and OTC products (posted January 20, 2026) — none of which involve metbufen specifically. Metbufen is a nonsteroidal anti-inflammatory drug (NSAID), yet the opportunities shown are soliciting naloxone (an opioid antagonist), prescription fulfillment infrastructure, and broad pharmaceutical catalog supply. The mismatch suggests either a tagging error in the source data or that metbufen procurement under this code shows little or no recent state and local activity. The Seminole County opportunity does identify a concrete pharmaceutical purchase process — competitive IFB for recurring annual volumes with quarterly deliveries, fixed-fee pricing, E-Verify compliance, and FEMA-related compliance — but that solicitation targets naloxone and drug deactivation systems rather than metbufen.

State and local governments do not appear to be soliciting metbufen as a standalone commodity under UNSPSC 51384102 based on recent posted opportunities. If your firm has metbufen or broader NSAID supply capabilities, monitor the broader pharmaceutical and OTC product RFPs such as MMCAP's multi-state cooperative purchasing vehicle, which coordinates pharma procurement across state and local participants. However, no current metbufen-specific demand is evident in the recent record.